{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:26:11Z","timestamp":1778185571482,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40265-017-0740-2","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T12:22:03Z","timestamp":1492518123000},"page":"777-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Reslizumab in Eosinophilic Asthma: A Review"],"prefix":"10.1007","volume":"77","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","unstructured":"de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1). doi:\n                        10.1183\/23120541.00024-2015\n                        \n                    .","DOI":"10.1183\/23120541.00024-2015"},{"key":"740_CR2","first-page":"125","volume":"8","author":"MF Patterson","year":"2015","unstructured":"Patterson MF, Borish L, Kennedy JL. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy. 2015;8:125\u201334.","journal-title":"J Asthma Allergy."},{"issue":"2","key":"740_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/rr41","volume":"2","author":"S Greenfeder","year":"2001","unstructured":"Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma: the role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71\u20139.","journal-title":"Respir Res"},{"key":"740_CR4","unstructured":"Teva Pharmaceuticals Ltd. Reslizumab (Cinqaero\u00ae): summary of product characteristics. 2016. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR5","unstructured":"Teva Respiratory LLC. Cinqair\u00ae (reslizumab) injection, for intravenous use: US prescribing information. 2016. \n                        http:\/\/www.cinqair.com\n                        \n                    . Accessed 28 Mar 2017."},{"issue":"9","key":"740_CR6","first-page":"779","volume":"49","author":"RW Egan","year":"1999","unstructured":"Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49(9):779\u201390.","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"740_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/intimm\/11.12.1935","volume":"11","author":"J Zhang","year":"1999","unstructured":"Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11(12):1935\u201344.","journal-title":"Int Immunol"},{"issue":"5","key":"740_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med."},{"issue":"4","key":"740_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789\u201398.","journal-title":"Chest"},{"issue":"4","key":"740_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799\u2013810.","journal-title":"Chest"},{"issue":"10","key":"740_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"740_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 2","key":"740_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1590\/S0074-02761997000800011","volume":"92","author":"RW Egan","year":"1997","unstructured":"Egan RW, Athwahl D, Chou CC, et al. Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz. 1997;92(Suppl 2):69\u201373.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"740_CR14","unstructured":"Jaworowicz D, Fiedler-Kelly J, Rabinovich-Guilatt L. The steady-state pharmacokinetic (PK) profile across a range of patient body weight categories supports weight-based dosing for intravenous (IV) reslizumab [abstract]. Am J Resp Crit Care Med. 2016;193(Meeting Abstracts):A1389."},{"key":"740_CR15","unstructured":"Murphy K, Jacobs J, Bjermer L. Long-term safety and efficacy of reslizumab in patients with inadequately controlled, moderate-to-severe asthma and elevated blood eosinophil counts: an open-label extension study [abstract no. 1025]. Am J Respir Crit Care Med. 2015;191(Meeting Abstracts):A6455."},{"key":"740_CR16","unstructured":"Bardin P, Murphy K, Garin M. Effect of reslizumab treatment on rescue systemic corticosteroid use in patients with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract no. A7783]. Am J Respir Crit Care Med. 2016;193(Meeting Abstracts)."},{"issue":"5 Suppl","key":"740_CR17","first-page":"A57","volume":"115","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Murphy K, Bjermer L. Long-term effect of reslizumab on asthma-related quality of life (AQLQ) in asthma patients (pts) previously enrolled in reslizumab safety and efficacy studies [abstract no. P62]. Ann Allergy Asthma Immunol. 2015;115(5 Suppl):A57.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"740_CR18","doi-asserted-by":"publisher","unstructured":"Weinstein SF, Germinaro M, Bardin P. Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils [abstract no. 283]. J Allergy Clin Immunol. 2016;137(2 Suppl):AB86.","DOI":"10.1016\/j.jaci.2015.12.409"},{"key":"740_CR19","doi-asserted-by":"publisher","unstructured":"Bernstein DI, Mansfield L, Zangrilli J. Efficacy of reslizumab in older patients (\u226565\u00a0years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract no. 284]. J Allergy Clin Immunol. 2016;137(2 Suppl):AB86.","DOI":"10.1016\/j.jaci.2015.12.410"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","volume":"43","author":"G Brusselle","year":"2017","unstructured":"Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39\u201345.","journal-title":"Pulm Pharmacol Ther"},{"key":"740_CR21","unstructured":"EMA. European public assessment report (EPAR): Cinqaero\u00ae (reslizumab). 2016. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR22","unstructured":"Data on file, Teva Pharmaceutical industries Ltd; 2017."},{"key":"740_CR23","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 153\u2014British guideline on the management of asthma. 2016. \n                        www.sign.ac.uk\/pdf\/SIGN153.pdf\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR24","unstructured":"Global Initiative for Asthma. 2017 GINA Report, global strategy for asthma management and prevention. 2017. \n                        http:\/\/ginasthma.org\n                        \n                    . Accessed 28 Mar 2017."},{"issue":"1","key":"740_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2049-6958-10-1","volume":"10","author":"F Menzella","year":"2015","unstructured":"Menzella F, Lusuardi M, Galeone C, et al. Tailored therapy for severe asthma. Multidiscip Respir Med. 2015;10(1):1.","journal-title":"Multidiscip Respir Med."},{"key":"740_CR26","unstructured":"Novartis Europharm Ltd. Xolair: summary of product characteristics. 2016. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR27","unstructured":"Genentech USA Inc and Novartis Pharmaceuticals Corporation. Xolair: US prescribing information. 2016. \n                        http:\/\/www.fda.gov\n                        \n                    . Accessed 28 Mar 2017."},{"issue":"4","key":"740_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40259-016-0182-5","volume":"30","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Mepolizumab: a review in eosinophilic asthma. BioDrugs. 2016;30(4):361\u201370.","journal-title":"BioDrugs."},{"key":"740_CR29","unstructured":"GlaxoSmithKline Trading Services Ltd. Nucala: summary of product characteristics. 2016. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR30","unstructured":"GlaxoSmithKline LLC. Nucala: US prescribing information. 2017. \n                        http:\/\/www.fda.gov\n                        \n                    . Accessed 28 Mar 2017."},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"31813","DOI":"10.3402\/ecrj.v3.31813","volume":"3","author":"E Papathanassiou","year":"2016","unstructured":"Papathanassiou E, Loukides S, Bakakos P. Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J. 2016;3:31813.","journal-title":"Eur Clin Respir J."},{"key":"740_CR32","unstructured":"National Institute for Health and Care Excellence. Appraisal consultation document. Reslizumab for treating eosinophilic asthma inadequately controlled by inhaled corticosteroids. 2016. \n                        https:\/\/www.nice.org.uk\n                        \n                    . Accessed 28 Mar 2017."},{"issue":"2","key":"740_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","volume":"118","author":"MD Whittington","year":"2017","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2147\/TCRM.S111862","volume":"12","author":"G Pelaia","year":"2016","unstructured":"Pelaia G, Vatrella A, Busceti MT, et al. Role of biologics in severe eosinophilic asthma\u2014focus on reslizumab. Ther Clin Risk Manag. 2016;12:1075\u201382.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0740-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0740-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0740-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T13:31:16Z","timestamp":1492867876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0740-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0740-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]}}}